Although Axsome is benefiting from Auvelity’s momentum and its broader commercial portfolio, the CNS space remains highly ...
A little-known treatment for heart failure, developed more than half a century ago and refined in the '70s, may have legs as a potential therapy for Alzheimer's patients.
Money Talks News on MSN
1 in 4 Medicare patients with dementia get risky drugs. 6 questions families should ask
The memory-care unit wants to calm Mom down with a pill. Before you say yes, there's something they may have skipped.
New research links repeated gabapentin use with increased risk, prompting cautious monitoring for gabapentin and dementia ...
Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimer’s revenue growth, and key risk/reward ...
Spread the loveImagine a world where an Alzheimer’s diagnosis doesn’t automatically mean an inevitable, rapid decline.
Arrowhead Pharmaceuticals, Inc. beats on ARO-MAPT with up to 85% CSF tau cut; CNS siRNA platform gains traction. Click for ...
The Cystic Fibrosis Foundation acknowledged the essential role of the NIH in a 2025 letter to Russell Vought and other Trump administration leaders, writing that “ensuring that the National Institutes ...
The medical marijuana competitive landscape report delivers important insights into approved as well as ongoing research of 65+ pipeline medical marijuana drugs, clinical strategies, upcoming ...
Axsome Therapeutics(NASDAQ: AXSM) entered 2026 with Auvelity already generating more than half a billion dollars in annual ...
Major medical strides are being made in the fight against Alzheimer’s disease, with new treatments and testing offering patients more options to slow cognitive decline and identify the disease earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results